NeuroOne Medical Technologies Corporation (NMTC) expects preliminary, unaudited fiscal fourth-quarter 2026 product revenue of approximately $3.8 million, up 38.4% year over year from approximately $2.7 million. For fiscal 2026, it expects product revenue of approximately $10.5 million, up 15.6% year over year and at the top of its previously announced $9.2 million to $10.5 million guidance range. The estimates are subject to year-end accounting and audit procedures.
NeuroOne received a $4.5 million product purchase order in September 2026. Approximately $1.0 million had shipped by September 30; shipments of the remaining $3.6 million are expected to begin during fiscal first quarter 2027 and extend into second quarter 2027, subject to manufacturing and delivery schedules. Open purchase orders for shipments through fiscal first quarter 2027 totaled $5.4 million as of September 30, 2026. Complete fourth-quarter and full-year results are expected in December 2026.
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Chief Business Officer David J. Wambeke reported two insider transactions. On August 27, 2026, he purchased 33,333 shares of common stock at a weighted average price of about $2.01 per share, with individual trade prices between $2.00 and $2.017, bringing his direct common share holdings to 199,999 shares. On August 28, 2026, he received a grant of 35,000 stock options with an exercise price of $1.77 per share, expiring on August 27, 2036; 25% of these options will vest on August 28, 2027 and the remaining 75% will vest in 12 equal quarterly installments. No Rule 10b5-1 trading plan is reported for these transactions.
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) reported that Chief Administrative Officer Emily J. Johns received a grant of stock options. The award covers 12,500 options to purchase common shares at an exercise price of $1.77 per share, expiring on August 27, 2036. Following this grant, she holds 12,500 options. According to the vesting terms, 25% of the options will vest on August 28, 2027, and the remaining 75% will vest in 12 equal quarterly installments thereafter.
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) reported that Chief Financial Officer Christopher Volker received a grant of options to purchase 35,000 shares of common stock. The options have an exercise price of $1.77 per share and expire on August 27, 2036. According to the vesting terms, 25% of the options will vest on August 28, 2027, and the remaining 75% will vest in 12 equal quarterly installments thereafter. Following this award, Volker holds 35,000 option shares directly from this grant.
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) reported that officer Mark Christianson received a grant of 12,500 options to purchase common stock. The options have an exercise price of $1.77 per share and expire on August 27, 2036. According to the vesting terms, 25% of the options vest on August 28, 2027, with the remaining 75% vesting in 12 equal quarterly installments thereafter. Following this award, Christianson directly holds 12,500 derivative securities related to NMTC common stock.
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) reported that Chief Technology Officer Steve Mertens received a grant of an option to purchase 15,000 shares of common stock. The option has an exercise price of $1.77 per share and expires on August 27, 2036. According to the vesting terms, 25% of the option will vest on August 28, 2027, with the remaining 75% vesting in 12 equal quarterly installments thereafter. Following this grant, Mertens holds 15,000 derivative securities directly.
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) reported that CEO and President David A. Rosa received a grant of stock options covering 68,000 shares of common stock. The options have an exercise price of $1.77 per share, expire on August 27, 2036, and are held directly. According to the vesting terms, 25% will vest on August 28, 2027, with the remaining 75% vesting in 12 equal quarterly installments. Following this award, he holds options to purchase 68,000 shares from this grant.
NeuroOne Medical Technologies Corporation (NMTC) reported successful completion of three large-animal procedures using its next-generation StereoCED™ platform for targeted brain drug delivery and electrophysiological monitoring. In two procedures, the company’s electrodes both delivered a study agent and recorded intracranial activity from the same targeted brain regions, which NeuroOne believes is a first in convection-enhanced delivery.
The procedures were conducted at the University of Minnesota as part of a preclinical epilepsy research program and were designed to establish technical feasibility and validate the robotic-assisted surgical and drug delivery workflow. NeuroOne states that development of StereoCED™ devices for animal use finished ahead of schedule, enabling earlier-than-anticipated sales, and expects to recognize related StereoCED™ revenue from this research program in fiscal Q4 2026. Development of devices for human investigational use is reported to be on track, with release planned by the end of fiscal Q4 2026 and a planned launch of human investigational clinical studies later in the quarter.
NeuroOne Medical Technologies Corporation reports continued operating losses and tight liquidity for the quarter and nine months ended June 30, 2026. Product revenue was $1.97 million for the quarter and $6.73 million for the nine months, modestly above the prior-year periods, but license revenue of $3.0 million recognized in 2025 did not recur.
The company posted a quarterly net loss of $2.01 million and a nine‑month net loss of $5.83 million, significantly larger than the prior‑year nine‑month loss of $1.99 million. Operating cash outflows rose to $5.53 million for the nine months, reducing cash and cash equivalents to $2.05 million and total assets to $6.19 million. Accumulated deficit reached $84.4 million.
Management discloses substantial doubt about the ability to continue as a going concern, estimating current cash plus post‑quarter ATM proceeds will fund operations only into January 2027. The business remains highly concentrated, with one customer contributing essentially all product revenue, and relies on equity financing, including an at‑the‑market program and a March 2026 private placement. A 1‑for‑6 reverse stock split was completed in April 2026 to address Nasdaq listing requirements.
NeuroOne Medical Technologies Corporation reported fiscal Q3 2026 results showing solid top-line growth but continued losses. Product revenue rose 16% year-over-year to $2.0 million, driven mainly by higher sales of OneRF products. Product gross profit increased 29% to $1.2 million, with product gross margin expanding to a record 59.9% versus 53.9% a year earlier.
New product orders of $2.7 million during the quarter exceeded shipments of $2.0 million, increasing backlog to $1.7 million, and total product orders for fiscal 2026 reached $11.2 million. However, total operating expenses grew to $3.6 million from $2.8 million, leading to a net loss of $2.0 million compared with a $1.5 million loss in the prior-year quarter.
As of June 30, 2026, cash and cash equivalents were $2.0 million, down from $6.6 million as of September 30, 2025, and working capital was $3.7 million versus $7.9 million. The company raised $0.4 million in Q3 and $8.4 million cumulatively through its at-the-market offering program, and later added $1.0 million more. NeuroOne reported no debt and highlighted ISO 13485 certification and planned international expansion and new therapy launches, including the StereoCED drug delivery system for research and investigational clinical studies by fiscal year-end.